970*90
768
468
mobile

M22 technology is for dry & itchy eyes caused by eyelid inflammation

Franchise India Bureau
Franchise India Bureau Oct 12 2017 - 2 min read
M22 technology is for dry & itchy eyes caused by eyelid inflammation
To cater with the solution of Dry Eye Syndrome, Lumenis Ltd, the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications

With an increasingly use of gadgets like mobiles phones, laptops and computers workaholic people are more prone to dry eye syndrome. Studies show that humans generally blink about 22 times a minute. But when we concentrate on a computer screen or a smart phone or even while driving, the rate goes down to five or seven blinks per minute. If this tear film does not spread sufficiently across the eye, it can lead to dryness and irritation.

To cater with the solution of Dry Eye Syndrome, Lumenis Ltd, the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications today launches its first ever Lumenis M22 OPT technology with Center for Sight in North India , in New Delhi.

Mr. Rashid Mokhdoomi, Senior Director, Marketing India and South Asia, Lumenis Said “With the launch of Optimum Pulse Technology (OPT) for Dry Eye disease, Lumenis helps address this growing disease with our path breaking technology. Meibomian Gland dysfunction (MGD) is one of the leading causes of Dry Eye disease (DED), affecting millions worldwide. Optimal pulse technology from Lumenis has emerged as the most effective alternative for patients with MGD. OPT leads to significant improvement in ocular surface quality, gland function and dry eye symptoms. We have also developed a Practice Enhancement Programs for Clinics; as we foresee rapid increase in demand for Dry Eye treatment with OPT technology. We continue to invest in our training and education platforms to ensure increasing number of patients benefit from the latest OPT technology.”

Dr. Mahipal S Sachdev, Chairman and Medical Director, Centre for Sight said “Technology has opened a new pathway for treating the patients who has to face a lot of problems related to the dry eye. Since, we always believed in bringing new technology to consumers, the new M22 OPT is infact a path breaking technology to the traditional used therapies”.

 

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry